Glyphosate-cancer legal battle raises investor doubts about Bayer’s purchase of Monsanto

Bayer Monsanto Merger

Bayer has to pay out $81 million in damages to a man who claims the Roundup weedkiller caused his cancer, a jury ruled [March 27]. In a similar ruling last year, the sum was $289 million, reduced to $78 million on appeal. Since that first verdict, Bayer’s shares have lost 40% of their value—and there are still around 11,300 such cases waiting in the wings.

All of which begs the question: was it foolhardy for Bayer to buy Roundup maker Monsanto?

Some, including activist Bayer shareholder Christian Strenger, say indeed it was. Strenger has filed a motion of no confidence in Bayer’s board ahead of the German giant’s annual general meeting [in April 2019], and it includes a litany of complaints about the “almost complete failure to deliver the key objectives presented by [Bayer CEO Werner] Baumann in May 2016 for the Monsanto acquisition.”

Related article:  China approves import of 5 GMO crops for animal feed, first since 2017


A [Bayer] spokesperson insists that, in the run-up to the Monsanto acquisition, Bayer’s board “performed this risk assessment based on an information and update process which was in all respects adequate for an acquisition of such a scale.”

Read full, original article: As Bayer’s Roundup Cancer Costs Accumulate, Questions Linger About the Wisdom of Its Monsanto Merger

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend